Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries: Data from the gulf registry of acute coronary events

Ibrahim Al-Zakwani, Mohammad Zubaid, Prashanth Panduranga, Wafa Rashed, Kadhim Sulaiman, Wael Almahmeed, Ahmed Al-Motarreb, Jassim Al Suwaidi, Haitham Amin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We evaluated the use of quadruple evidence-based medication (EBM) combination consisting of antiplatelet therapy, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and lipid-lowering agent concurrently at discharge among patients (n = 8154) with acute coronary syndrome (ACS) in 6 Middle Eastern countries. In all, 49% of the patients received the quadruple EBM combination concurrently at discharge. An adjusted model demonstrated that old age, diabetes mellitus, hyperlipidemia, hypertension, ST-segment elevation myocardial infarction, cardiac catheterization, as well as cardiologists as care providers and hospitals with cardiac catheterization facilities were all positively correlated with the use of the quadruple EBM combination. However, patients with cardiogenic shock, renal impairment, higher risk score, congestive heart failure, recurrent ischemia, and those admitted to academic hospitals were negatively correlated with the use of the quadruple EBM combination. Guideline adherence to the concurrent use of quadruple EBM combination in patients with ACS at discharge was suboptimal with wide disparity among the 6 countries.

Original languageEnglish
Pages (from-to)447-454
Number of pages8
JournalAngiology
Volume62
Issue number6
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Acute Coronary Syndrome
Registries
Cardiac Catheterization
Guideline Adherence
Cardiogenic Shock
Patient Discharge
Angiotensin Receptor Antagonists
Hyperlipidemias
Angiotensin-Converting Enzyme Inhibitors
Diabetes Mellitus
Therapeutics
Ischemia
Heart Failure
Hypertension
Kidney
Lipids

Keywords

  • acute coronary syndrome
  • antihypertensive agents
  • antiplatelet drugs
  • coronary heart disease
  • evidence-based medications
  • Middle East
  • statin
  • treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries : Data from the gulf registry of acute coronary events. / Al-Zakwani, Ibrahim; Zubaid, Mohammad; Panduranga, Prashanth; Rashed, Wafa; Sulaiman, Kadhim; Almahmeed, Wael; Al-Motarreb, Ahmed; Al Suwaidi, Jassim; Amin, Haitham.

In: Angiology, Vol. 62, No. 6, 08.2011, p. 447-454.

Research output: Contribution to journalArticle

Al-Zakwani, Ibrahim ; Zubaid, Mohammad ; Panduranga, Prashanth ; Rashed, Wafa ; Sulaiman, Kadhim ; Almahmeed, Wael ; Al-Motarreb, Ahmed ; Al Suwaidi, Jassim ; Amin, Haitham. / Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries : Data from the gulf registry of acute coronary events. In: Angiology. 2011 ; Vol. 62, No. 6. pp. 447-454.
@article{b03ba710980b4a738aef439cc74da118,
title = "Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries: Data from the gulf registry of acute coronary events",
abstract = "We evaluated the use of quadruple evidence-based medication (EBM) combination consisting of antiplatelet therapy, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and lipid-lowering agent concurrently at discharge among patients (n = 8154) with acute coronary syndrome (ACS) in 6 Middle Eastern countries. In all, 49{\%} of the patients received the quadruple EBM combination concurrently at discharge. An adjusted model demonstrated that old age, diabetes mellitus, hyperlipidemia, hypertension, ST-segment elevation myocardial infarction, cardiac catheterization, as well as cardiologists as care providers and hospitals with cardiac catheterization facilities were all positively correlated with the use of the quadruple EBM combination. However, patients with cardiogenic shock, renal impairment, higher risk score, congestive heart failure, recurrent ischemia, and those admitted to academic hospitals were negatively correlated with the use of the quadruple EBM combination. Guideline adherence to the concurrent use of quadruple EBM combination in patients with ACS at discharge was suboptimal with wide disparity among the 6 countries.",
keywords = "acute coronary syndrome, antihypertensive agents, antiplatelet drugs, coronary heart disease, evidence-based medications, Middle East, statin, treatment",
author = "Ibrahim Al-Zakwani and Mohammad Zubaid and Prashanth Panduranga and Wafa Rashed and Kadhim Sulaiman and Wael Almahmeed and Ahmed Al-Motarreb and {Al Suwaidi}, Jassim and Haitham Amin",
year = "2011",
month = "8",
doi = "10.1177/0003319710394163",
language = "English",
volume = "62",
pages = "447--454",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries

T2 - Data from the gulf registry of acute coronary events

AU - Al-Zakwani, Ibrahim

AU - Zubaid, Mohammad

AU - Panduranga, Prashanth

AU - Rashed, Wafa

AU - Sulaiman, Kadhim

AU - Almahmeed, Wael

AU - Al-Motarreb, Ahmed

AU - Al Suwaidi, Jassim

AU - Amin, Haitham

PY - 2011/8

Y1 - 2011/8

N2 - We evaluated the use of quadruple evidence-based medication (EBM) combination consisting of antiplatelet therapy, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and lipid-lowering agent concurrently at discharge among patients (n = 8154) with acute coronary syndrome (ACS) in 6 Middle Eastern countries. In all, 49% of the patients received the quadruple EBM combination concurrently at discharge. An adjusted model demonstrated that old age, diabetes mellitus, hyperlipidemia, hypertension, ST-segment elevation myocardial infarction, cardiac catheterization, as well as cardiologists as care providers and hospitals with cardiac catheterization facilities were all positively correlated with the use of the quadruple EBM combination. However, patients with cardiogenic shock, renal impairment, higher risk score, congestive heart failure, recurrent ischemia, and those admitted to academic hospitals were negatively correlated with the use of the quadruple EBM combination. Guideline adherence to the concurrent use of quadruple EBM combination in patients with ACS at discharge was suboptimal with wide disparity among the 6 countries.

AB - We evaluated the use of quadruple evidence-based medication (EBM) combination consisting of antiplatelet therapy, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and lipid-lowering agent concurrently at discharge among patients (n = 8154) with acute coronary syndrome (ACS) in 6 Middle Eastern countries. In all, 49% of the patients received the quadruple EBM combination concurrently at discharge. An adjusted model demonstrated that old age, diabetes mellitus, hyperlipidemia, hypertension, ST-segment elevation myocardial infarction, cardiac catheterization, as well as cardiologists as care providers and hospitals with cardiac catheterization facilities were all positively correlated with the use of the quadruple EBM combination. However, patients with cardiogenic shock, renal impairment, higher risk score, congestive heart failure, recurrent ischemia, and those admitted to academic hospitals were negatively correlated with the use of the quadruple EBM combination. Guideline adherence to the concurrent use of quadruple EBM combination in patients with ACS at discharge was suboptimal with wide disparity among the 6 countries.

KW - acute coronary syndrome

KW - antihypertensive agents

KW - antiplatelet drugs

KW - coronary heart disease

KW - evidence-based medications

KW - Middle East

KW - statin

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79960958649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960958649&partnerID=8YFLogxK

U2 - 10.1177/0003319710394163

DO - 10.1177/0003319710394163

M3 - Article

C2 - 21421625

AN - SCOPUS:79960958649

VL - 62

SP - 447

EP - 454

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 6

ER -